現場の疑問に答える 周産期医療Q&A

出版社: 中外医学社
著者:
発行日: 2022-07-30
分野: 臨床医学:外科  >  産婦人科学
ISBN: 9784498160361
電子書籍版: 2022-07-30 (1版1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

5,720 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,720 円(税込)

商品紹介

標準治療指針・ガイドラインの推奨だけでは対処できない実臨床で使える,現実的な診療の技を学び,臨床力をUPしよう.外来診療も産科救急も! 臨床で実際に生じる疑問に答えた現場で本当に役立つ1冊.一歩踏み込んだガイドラインを補完する知識を,具体的な症例と共にエキスパートが伝授!

目次

  • 第1章 産科外来における疑問
     Q1 高血圧を合併し妊娠を希望する女性に,妊娠の可否やリスクを問われた場合の
        対応を教えてください
     Q2 VTE既往があり妊娠を希望する女性に,妊娠の可否を問われた際や,
        リスク時の対応を教えてください
     Q3 重症の妊娠高血圧症候群の既往がある妊婦の取り扱いを教えてください
     Q4 SGA児の出産の既往がある妊婦の取り扱いを教えてください
     Q5 常位胎盤早期剝離の既往がある妊婦の取り扱いを教えてください
     Q6 妊婦初期検査においてトキソプラズマ抗体陽性であった妊婦の取り扱いを教えてください
     Q7 重篤な妊娠悪阻の場合に推奨される検査,鑑別と対応を教えてください
     Q8 妊娠初期に膜性診断されていない双胎妊娠の取り扱いを教えてください
     Q9 付属器に腫瘤を認める妊婦の取り扱いを教えてください
     Q10 子宮頸管が妊娠中期に短縮した症例の取り扱いを教えてください
     Q11 妊娠中期・後期になり尿蛋白が(2+)程度持続的に陽性となるも
        血圧が正常である妊婦の取り扱いを教えてください
     Q12 妊婦への無症候性細菌尿のscreeningについて教えてください
     Q13 34週以降の早産であるlate preterm birthの既往がある妊婦の取り扱いを教えてください
     Q14 妊娠中期に性器出血を主訴に受診した妊婦の対応を教えてください
     Q15 妊娠初期中期に新型コロナウイルスに感染した妊婦の取り扱いを教えてください
     Q16 帝王切開創部の極端な菲薄化を認めた妊婦の取り扱いを教えてください
     Q17 妊娠37週以降の正期産期の羊水過少に対する対応について,
        分娩誘発の適応や留意点を教えてください

    第2章 産科救急についての疑問
     Q1 超緊急帝王切開にそなえた施設としての準備や他の診療科との連携を教えてください
     Q2 分娩進行中に妊婦に痙攣発作を認めた場合の鑑別と対応を教えてください
     Q3 分娩時の血圧上昇に対して,降圧薬と硫酸マグネシウムのそれぞれの適応,
        使い分け,具体的な使用方法を教えてください
     Q4 陣痛発来で来院した妊婦に新型コロナウイルス感染症が疑われる場合の対応を教えてください
     Q5 産科危機的出血における子宮内バルーンタンポナーデの適応について教えてください.
        また,バルーンの使用法を教えてください
     Q6 危機的産科出血におけるIVR治療の適応と実際を教えてください
     Q7 羊水塞栓症の診断と対処方法について,とりわけ消費性凝固障害の視点から教えてください
     Q8 産科危機的出血におけるフィブリノゲン製剤やクリオプレシピテートの実際と
        ノボセブンの適応との違いを教えてください
     Q9 産科救急における複数診療科の連携につき,施設としての取り組みを教えてください
     Q10 死戦期帝王切開に備えた施設としての準備や院内の連携を教えてください
     Q11 母体死亡があった場合の適切な対応を教えてください
     Q12 硬膜外無痛分娩における局所麻酔薬中毒や全脊椎麻酔の診断のポイントや
        適切な対応を教えてください
     Q13 妊婦の敗血症についての診断と治療のポイントを教えてください
     Q14 母体救命のスキルアップについて教えてください

    第3章 児の長期予後についての疑問
     Q1 神経性やせ症などによる重度のやせ妊婦の取り扱いを教えてください.
        また,子どもの将来の健康について教えてください
     Q2 高度肥満(BMI 35以上)の取り扱いを教えてください.
        また子どもの将来の健康について教えてください
     Q3 妊娠中に投与された抗菌薬や妊婦の食事と母や児の腸内細菌叢との関連について教えてください
     Q4 妊娠糖尿病の妊婦より出生した児の長期予後について教えてください.
        また,妊娠糖尿病を発症した妊婦の将来の2型糖尿病発症リスクを教えてください
     Q5 妊娠中の向精神薬や抗てんかん薬の内服は生まれた子どもに影響しますか.教えてください

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 産科外来における疑問

P.7 掲載の参考文献
1) 日本妊娠高血圧学会. 妊娠高血圧症候群の診療指針 2021. 東京 : メジカルビュー社. 2021.
2) 日本高血圧学会高血圧治療ガイドライン作成委員会, 編. 高血圧治療ガイドライン 2019. 東京 : ライフサイエンス出版. 2019.
3) Nzelu D, Dumitrascu-Biris D, Nicolaodes KH, et al. Chronic hypertension : First trimester blood pressure control and likelihood of severe hepertension, preeclampsia and small for gestational age. Am J Obstet Gynecol. 2018 ; 218 : 337e1-7.
4) Magee LA, Singer J, von Dadelszen P : CHIPS Study Group. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015 ; 372 : 2367-8.
5) Poon LC, Wright D, Rolnik DL, et al. Aspirin for evidence-based preeclampsia prevention trial : effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol. 2017 ; 217 : 585.e1-5.
6) Banala C, Moreno S, Cruz Y, et al. Impact of the ACOG guideline regarding low-dose aspirin for prevention of superimposed preeclampsia in women with chronic hypertension. Am J Obstet Gynecol. 2020 ; 223 : 419.e1-16.
7) The National Institution for Health and Care Excellence. Hypertension in pregnancy : diagnosis and management. NICE guideline. 2019. p.9-54.
8) American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 203 : Chronic hypertension in pregnancy. Obstet Gynecol. 2019 ; 133 : e26-50.
P.17 掲載の参考文献
1) 杉村基. 血栓性疾患の治療薬 産科領域における抗血栓療法の特殊性 (産婦人科の立場より). 日血栓止血会誌. 2019 ; 30 : 125-9.
2) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン産科編 2020. 2020.
3) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. American College of Chest Physicians Evidence-Based Clnical Practice Guidelines (9th Edition). 2012 ; 141 : e691S-736S.
4) Royal College of Obstetrician and Gynaecologist. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. Green-top Guideline No. 37a. 2015. p.1-40.
5) Bates AM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism : venous thromboembolism in the context of pregnancy. Blood Adv. 2018 ; 2 : 3317-59.
6) 厚生労働科学研究費補助金難治性疾患政策研究事業血液凝固異常症等に関する研究特発性血栓症研究グループ, 編. 遺伝性血栓性素因患者の妊娠分娩管理に関する診療の手引き Q&A. 日産婦新生児血会誌. 2021 ; 30 : 5-21.
7) 妊産婦死亡症例検討評価委員会, 日本産婦人科医会. 妊産婦死亡の原因について. 母体安全への提言 2017. 2018. p.12-4.
P.27 掲載の参考文献
1) Andersgaard AB, Achaya G, Mathiesen EB, et al. Recurrence and long-term maternal health risks of hypertensive disorders of pregnancy : a population-based study. Am J Obstet Gynecol. 2012 ; 206 : 143. e1-8.
2) 渡辺員支. 妊娠高血圧症候群 新定義・分類 運用上のポイント. 東京 : メジカルビュー社. 2019 ; p.8-15.
3) Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. Obstet Gynecol. 2007 ; 110 : 128-33.
4) Melamed N, Hadar E, Peled Y, et al. Risk for recurrence of preeclampsia and outcome of subsequent pregnancy in women with preeclampsia in their first pregnancy. J Matern Fetal Neonatal Med. 2012 ; 25 : 2248-51.
5) Lykke JA, Paidas MJ, Langhoff-Roos J. Recurring complications in second pregnancy. Obstet Gynecol. 2009 ; 113 : 1217-24.
6) Mbah AK, Alio AP, Marty PJ, et al. Pre-eclampsia in the first pregnancy and subsequent risk of stillbirth in black and white gravidas. Eur J Obstet Gynecol Reprod Biol. 2010 ; 149 : 165-9.
7) Zhang J, Troendle JF, Levine RJ. Risks of hypertensive disorders in the second pregnancy. Paediatr Perinat Epidemiol. 2001 ; 15 : 226-31.
8) 日本妊娠高血圧学会. 妊娠高血圧症候群の診療指針 2015. 東京 : メジカルビュー社. 2015 ; p.239-40, 241-3.
9) Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1 : PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016 ; 374 : 13-22.
10) Ohkuchi A, Saito S, Yamamoto T, et al. Short-term prediction of preeclampsia using the sFlt-1/PlGF ratio : a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study. Hypertens Res. 2021 ; 44 : 813-21.
12) Poon LC, Wight D, Rplnik DL, et al. Aspirin for evidence-based preeclampsia prevention trial : effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol. 2017 ; 217 : 585. e1-5.
13) Wright D, Poon LC, Rolnik DL, et al. Aspirin for evidence-based preeclampsia prevention trial : influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017 ; 217 : 685. e1-5.
14) Wright D, Rolnik DL, Syngelaki A, et al. Aspirin for evidence-based preeclampsia prevention trial : effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol. 2018 ; 218 : 612. e1-6.
15) Gu W, Lin J, Hou Y-Y, et al. Effects of low-dose aspirin on the prevention of preeclampsia and pregnancy outcomes : a randomized controlled trial from Shanghai, China. Eur J Obstet Gynecol Reprod Biol. 2020 ; 248 : 156-63.
16) ACOG Practice Bulletin No. 202 : Gestational Hypertension and Preeclampsia, ACOG Committee on Practice Bulletin. Obstet Gynecol. 2019 ; 133 : e1-25.
17) The National Institute for Health and Care Excellence : Hypertension in pregnancy : diagnosis and management. NICE guideline. 2019. p.9-54.
18) Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy : ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018 ; 13 : 291-310.
19) CQ309-2 妊娠高血圧症候群と診断されたら? In : 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン-産科編 2020. 2020. p.172-6.
20) Berks D, Hoedjes M, Raat H, et al. Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions : a literature-based study. BJOG. 2013 ; 120 : 924-31.
21) Irgens HU, Reisaeter L. Irgens LM, et al. Long term mortality of mothers and fathers after pre-eclampsia : population based cohort study. BMJ. 2001 ; 323 : 1213-7.
22) Kurabayashi T, Mizunuma H, Kubota T, et al. Pregnancy-induced hypertension is associated with maternal history and a risk of cardiovascular disease in later life : Japanese cross-sectional study. Maturitas. 2013 ; 75 : 227-31.
23) Watanabe K, Kimura C, Iwasaki A, et al. Pregnancy-induced hypertension is associated with an increase in the prevalence of cardiovascular disease risk factors in Japanese women. Menopause. 2015 ; 22 : 656-9.
24) Mito A, Arata N, Sakamoto N, et al. Hypertensive disorders of pregnancy : a strong risk factor for subsequent hypertension 5 years after delivery. Hypertension Res. 2018 ; 41 : 141-6.
25) Oishi M, Iino K, Tanaka K, et al. Hypertensive disorders of pregnancy increase the risk for chronic kidney disease : a population-based retrospective study. Clin Exp Hypertens. 2017 ; 39 : 361-5.
P.34 掲載の参考文献
1) Bhamidipaty-Pelosi S, Fox J, Greer RM, et al. The risks of recurrent small for gestational age infants at term is dependent on the number of previous affected births. Am J Obstet Gynecol. 2021 ; 225 : 415.e1-9.
2) Levy M, Alberti D, Kovo M, et al. Placental pathology in pregnancies complicated by fetal growth restriction : recurrence vs. new onset. Arch Gynecol Obstet. 2020 ; 301 : 1397-404.
3) CQ3 産科的APSのリスクにあった治療方法は? In : 平成27年度日本医療研究開発機構成育疾患克服等総合研究事業「抗リン脂質抗体症候群合併妊娠の治療及び予後に関する研究」研究班, 編. 抗リン脂質抗体症候群合併妊娠の診療ガイドライン. 東京 : 南山堂. 2016 ; p.24-31.
4) Kvalvik LG, Haug K, Klungsoyr K, et al. Maternal smoking status in successive pregnancies and risk of having a small for gestational age infant. Paediatr Perinat Epidemiol. 2017 ; 31 : 21-8.
5) Yamada H, Tanimura K, Tairaku S, et al. Clinical factor associated with congenital cytomegalovirus infection in pregnant women with non-primary infection. J Infect Chemother. 2018 ; 24 : 702-6.
6) Linde LE, Rasmussen S, Kessler J, et al. Extreme umbilical cord lengths, cord knot and entanglement : risk factors and risk of adverse outcomes, a population-based study. PLoS One. 2018 ; 13 : e0194814.
7) Tao RX, Meng DH, Li JJ, et al. Current recommended vitamin D prenatal supplementation and fetal growth : results from the China-Anhui Birth Cohort Study. J Clin Endocrinol Metab. 2018 ; 103 : 244-52.
8) Yusuf KK, Salihu HM, Wilson R, et al. Comparing folic acid dosage strengths to prevent reduction in fetal size among pregnant women who smoked cigarettes : a randomized clinical trial. JAMA Pediatr. 2019 ; 173 : 493-4.
9) Fetal Growth Restriction : ACOG Practice Bulletin, Number 227. Obstet Gynecol. 2021 ; 137 : e16-28.
P.40 掲載の参考文献
1) 日本産科婦人科学会. 産科婦人科用語集・用語解説集 改訂第4版. 2018.
2) Cunningham FG, Leveno KJ, Bloom SL, et al. Williams Obstetrics. 25th ed. New York : McGraw-Hill Professional ; 2018. p.767-73.
3) 日本医療機能評価制度. 産科医療補償制度 常位胎盤早期剥離について. 第6回報告書.
4) Ananth CV, Berkowitz GS, Savitz DA, et al. Placental abruption and adverse perinatal outcomes. JAMA. 1999 ; 282 : 1646-51.
5) Furuhashi M, Kurauchi O, Suganuma N. Pregnancy following placental abruption. Arch Gynecol Obstet. 2002 ; 267 : 11-3.
6) Ruiter L, Ravelli ACJ, de Graaf IM, et al. Incidence and recurrence rate of placental abruption : a longitudinal linked national cohort study in the Netherlands. Am J Obstet Gynecol. 2015 ; 213 : 573.e1-8.
P.46 掲載の参考文献
1) Ortiz-Alegria LB, Caballero-Ortega H, Canedo-Solares I, et al. Congenital toxoplasmosis : candidate host immune genes relevant for vertical transmission and pathogenesis. Genes Immun. 2010 ; 11 : 363-73.
2) Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004 ; 363 : 1965-76.
3) Hohlfeld P, Daffos F, Costa JM, et al. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med. 1994 ; 331 : 695-9.
4) Berrebi A, Kobuch WE. Toxoplasmosis in pregnancy. Lancet. 1994 ; 344 : 950.
5) Dubey JP. Toxoplasma gondii infections in chickens (Gallus domesticus) : prevalence, clinical disease, diagnosis and public health significance. Zoonoses Public Health. 2010 ; 57 : 60-73.
6) Hill DE, Haley C, Wagner B, et al. Seroprevalence of and risk factors for Toxoplasma gondii in the US swine herd using sera collected during the National Animal Health Monitoring Survey (Swine 2006). Zoonoses Public Health. 2010 ; 57 : 53-9.
7) Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii : from animals to humans. Int J Parasitol. 2000 ; 30 : 1217-58.
8) Yamada H, Tanimura K, Deguchi M, et al. A cohort study of maternal screening for congenital Toxoplasma gondii infection : 12 years' experience. J Infect Chemother. 2019 ; 25 : 427-30.
P.53 掲載の参考文献
1) Matthews A, Haas DM, O'Mathuna DP, et al. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2015 ; 2015 : CD007575.
2) Herrell HE. Nausea and vomiting of pregnancy. Am Fam Physician. 2014 ; 89 : 965-70.
3) Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy : A prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol. 2000 ; 182 : 931-7.
4) Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract. 1993 ; 43 : 245-8.
5) Festin M. Nausea and vomiting in early pregnancy. BMJ Clin Evid. 2014 ; 2014 : 1405.
6) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189 : Nausea and vomiting of pregnancy. Obstet Gynecol. 2018 ; 131 : e15-30.
7) Broussard CN, Richter JE. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am. 1998 ; 27 : 123-51.
8) Hussain N, Selvakumari N, Afadapa F, et al. Pregnancy and gastric cancer : diagnostic and treatment dilemma. BMJ Case Rep. 2018 ; 2018 : bcr2017222963.
9) Gomes CF, Sousa M, Lourenco I, et al. Gastrointestinal diseases during pregnancy : what does the gastroenterologist need to know? Ann Gastroenterol. 2018 ; 31 : 385-94.
10) Burch R. Headache in pregnancy and the puerperium. Neurol Clin. 2019 ; 37 : 31-51.
11) 日本ビタミン学会, 編. ビタミンB1. 欠乏症の臨床. ビタミン総合事典. 東京 : 朝倉書店. 2010 ; p.172-9.
12) Abas MN, Tan PC, Azmi N, et al. Ondansetron compared with metoclopramide for hyperemesis gravidarum : a randomized controlled trial. Obstet Gynecol. 2014 ; 123 : 1272-9.
13) Carstairs SD. Ondansetron use in pregnancy and birth defects : A systematic review. Obstet Gynecol. 2016 ; 127 : 878-83.
P.64 掲載の参考文献
1) Adegbite AL, Castille S, Ward S, et al. Neuromorbidity in preterm twins in relation to chorionicity and discordant birth weight. Am J Obstet Gynecol. 2004 ; 190 : 156-63.
2) Minakami H, Honma Y, Matsubara S, et al. Effects of placental chorionicity on outcome in twin pregnancies. A cohort study. J Reprod Med. 1999 ; 44 : 595-600.
3) 村越毅, 上田敏子, 松本美奈子, 他. 多胎妊娠の短期および長期予後の検討. 日周産期・新生児誌. 2005 ; 41 : 750-5.
4) Ortibus E, Lopriore E, Deprest J, et al. The pregnancy and long-term neurodevelopmental outcome of monochorionic diamniotic twin gestations : a multicenter prospective cohort study from the first trimester onward. Am J Obstet Gynecol. 2009 ; 200 : 494 : e1-8.
5) Hack KE, Derks JB, Elias SG, et al. Increased perinatal mortality and morbidity in monochorionic versus dichorionic twin pregnancies : clinical implications of a large Dutch cohort study. BJOG. 2008 ; 115 : 58-67.
6) Sebire NJ, Souka A, Skentou H, et al. Early prediction of severe twin-to-twin transfusion syndrome. Hum Reprod. 2000 ; 15 : 2008-10.
7) Nakayama S, Ishii K, Kawaguchi H, et al. Perinatal outcome of monochorionic diamniotic twin pregnancies managed from early gestation at a single center. J Obstet Gynaecol Res. 2012 ; 38 : 692-7.
8) Baxi LV, Walsh CA. Monoamniotic twins in contemporary practice : a single-center study of perinatal outcomes. J Matern Fetal Neonatal Med. 2010 ; 23 : 506-10.
9) Hack KE, Derks JB, Schaap AH, et al. Perinatal outcome of monoamniotic twin pregnancies. Obstet Gynecol. 2009 ; 113 (2 Pt 1) : 353-60.
10) Murata M, Ishii K, Kamitomo M, et al. Perinatal outcome and clinical features of monochorionic monoamniotic twin gestation. J Obstet Gynaecol Res. 2013 ; 39 : 922-5.
11) Chmait RH, Floyd R, Benirschke K. Duplicity : sonography suggested a twin gestation was dichorionic- and monochorionic. Am J Obstet Gynecol. 2011 ; 205 : 87.e1-2.
12) Yamashita A, Ishii K, Hidaka N, et al. Monochorionic monozygotic twin pregnancy complicated with twin-twin transfusion syndrome presenting with an obvious lambda sign in the first trimester. Fetal Diagn Ther. 2015 ; 37 : 154-6.
13) Soga E, Murakoshi T, Terada S, et al. Changes in the ultrasonographical appearance of intertwin-dividing membrane of monochorionic diamniotic twin pregnancy. Twin Res Hum Genet. 2021 ; 24 : 130-2.
16) Konno H, Murakoshi T, Soga E, et al. Bipartite monochorionic diamniotic placenta without intertwin vascular anastomoses. Jpn J Med Ultrasonics. 2019 ; 46 : 555-8.
17) Lopriore E, Sueters M, Middeldorp JM, et al. Twin pregnancies with two separate placental masses can still be monochorionic and have vascular anastomoses. Am J Obstet Gynecol. 2006 ; 194 : 804-8.
18) Konno H, Murakoshi T, Miura K, et al. The incidence of dichorionic diamniotic twin pregnancy after single blastocyst embryo transfer and zygosity : 8 years of single-center experience. Twin Res Hum Genet. 2020 ; 23 : 51-4.
19) Kyono K, Nakajo Y, Nishinaka C, et al. A birth of twins-one boy and one girl-from a single embryo transfer and a possible natural pregnancy. J Assist Reprod Genet. 2009 ; 26 : 553-4.
20) Zou Z, Huang L, Lin S, et al. Unusual twinning : additional findings during prenatal diagnosis of twin zygosity by single nucleotide polymorphism (SNP) array. Prenatal Diagnosis. 2018 ; 38 : 428-34.
21) Murakoshi T. Genetics in Multiple Gestation. In : Masuzaki H, ed. Fetal Morph Functional Diagnosis. Comprehensive Gynecology and Obstetrics. Singapore : Springer Nature Singapore ; 2021. p.169-82.
22) Murakoshi T, Ishii K, Matsushita M, et al. Monochorionic monoamniotic twin pregnancies with two yolk sacs may not be a rare finding : a report of two cases. Ultrasound Obstet Gynecol. 2010 ; 36 : 384-6.
P.71 掲載の参考文献
1) Naqvi M, Kaimal A. Adnexal masses in pregnancy. Clin Obstet Gynecol. 2015 ; 58 : 93-101.
2) Leiserowitz GS, Xing G, Cress R, et al. Adnexal masses in pregnancy : how often are they malignant? Gynecol Oncol. 2006 ; 101 : 315-21.
3) Smith LH, Dalrymple JL, Leiserowitz GS, et al. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol. 2001 ; 184 : 1504-12.
4) Hoover K, Jenkins TR. Evaluation and management of adnexal mass in pregnancy. Am J Obstet Gynecol. 2011 ; 205 : 97-102.
5) Telischak NA, Yeh BM, Joe BN, et al. MRI of adnexal masses in pregnancy. AJR Am J Roentgenol. 2008 ; 191 : 364-70.
6) Timmerman D, Testa AC, Bourne T, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008 ; 31 : 681-90.
7) Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery : prospective validation by IOTA group. BMJ. 2010 ; 341 : c6839.
8) Testa AC, Mascilini F, Quagliozzi L, et al. Management of ovarian masses in pregnancy : patient selection for interventional treatment. Int J Gynecol Cancer. 2021 ; 31 : 899-906.
9) 日本産科婦人科学会, 日本産婦人科医会. CQ504 妊娠中に発見された付属器腫瘤の取り扱いは? In : 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2020. 2020. p.286-7.
10) Bidus MA, Ries A, Magann EF, et al. Markedly elevated beta-hCG levels in a normal singleton gestation with hyperreactio luteinalis. Obstet Gynecol. 2002 ; 99 : 958-61.
11) Webb KE, Sakhel K, Chauhan SP, et al. Adnexal mass during pregnancy : A review. Am J Perinatol. 2015 ; 32 : 1010-6.
P.81 掲載の参考文献
1) To MS, Alfirevic Z, Heath VCF, et al. Cervical cerclage for prevention of preterm delivery in women with short cervix : randomised controlled trial. Lancet. 2004 ; 363 : 1849-53.
2) Heath VC, Souka AP, Erasmus I, et al. Cervical length at 23 weeks of gestation : the value of Shirodkar suture for the short cervix. Ultrasound Obstet Gynecol. 1998 ; 12 : 318-22.
3) Rust OA, Atlas RO, Jones KJ, et al. A randomized trial of cerclage versus no cerclage among patients with ultrasonographically detected second-trimester preterm dilatation of the internal os. Am J Obstet Gynecol. 2000 ; 183 : 830-5.
4) Rust OA, Atlas RO, Reed J, et al. Revisiting the short cervix detected by transvaginal ultrasound in the second trimester : why cerclage therapy may not help. Am J Obstet Gynecol. 2001 ; 185 : 1098-105.
5) Althuisius SM, Dekker GA, van Geijn HP, et al. Cervical incompetence prevention randomized cerclage trial (CIPRACT) : study design and preliminary results. Am J Obstet Gynecol. 2000 ; 183 : 823-9.
6) Althuisius SM, Dekker GA, Hummel P, et al. Final results of the Cervical Incompetence Prevention Randomized Cerclage Tria (l CIPRACT) : Therapeutic cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol. 2001 ; 185 : 1106-12.
7) Althuisius SM, Dekker GA, Hummel P, et al. Cervical incompetence prevention randomized cerclage trial : emergency cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol. 2003 ; 189 : 907-10.
8) Sakai M, Shiozaki A, Tabata M, et al. Evaluation of effectiveness of prophylactic cerclage of a short cervix according to interleukin-8 in cervical mucus. Am J Obstet Gynecol. 2006 ; 194 : 14-9.
9) Alfirevic Z, Stampalija T, Medley N. Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database Syst Rev. 2017 ; 6 : CD008991.
10) ACOG Practice Bulletin No. 142 : Cerclage for the management of cervical insufficiency. Obstet Gynecol. 2014 ; 123 (2 Pt 1) : 372-9.
11) Otsuki K, Nakai A, Matsuda Y, et al. Randomized trial of ultrasound-indicated cerclage in singleton women without lower genital tract inflammation. J Obstet Gynaecol Res. 2016 ; 42 : 148-57.
12) Berghella V, Ciardulli A, Rust OA, et al. Cerclage for short cervix on ultrasound in singleton gestations without prior spontaneous preterm birth : a systematic review and meta-analysis of trials using individual patient-level data. Ultrasound Obstet Gynecol. 2017.
13) 大槻克文. 産科医ならマスターしたい子宮頸管縫縮術. 東京 : メジカルビュー社, 2020.
14) Kurup M, Goldkrand JW. Cervical incompetence : elective, emergent, or urgent cerclage. Am J Obstet Gynecol. 1999 ; 181 : 240-6.
15) Cardosi RJ, Chez RA. Comparison of elective and empiric cerclage and the role of emergency cerclage. J Matern Fetal Med. 1998 ; 7 : 230-4.
16) Wu MY, Yang YS, Huang SC, et al. Emergent and elective cervical cerclage for cervical incompetence. Int J Gynaecol Obstet. 1996 ; 54 : 23-9.
17) Terkildsen MFC, Parilla BV, Kumar P, et al. Factors associated with success of emergent second-trimester cerclage. Obstet Gynecol. 2003 ; 101 : 565-9.
18) Latta RA, McKenna B. Emergent cervical cerclage : predictors of success or failure. J Matern Fetal Med. 1996 ; 5 : 22-7.
19) MacDougall J, Siddle N. Emergency cervical cerclage. Br J Obstet Gynaecol. 1991 ; 98 : 1234-8.
20) Cunningham FG, Bloom SL, Spong C, et al. Williams Obstetrics. 24th ed. New York : McGraw-Hill Professiona. 2014.
21) 辻啓. 「腟式腹膜開放術式」によるShirodkar法. In : 最新婦人科手術. 大阪 : 永井書店. 1990 ; p.90-5.
22) Aarts JM, Brons JT, Bruinse HW. Emergency cerclage : a review. Obstet Gynecol Surv. 1995 ; 50 : 459-69.
23) Son GH, Chang KH-J, Song JE, et al. Use of a uniconcave balloon in emergency cerclage. Am J Obstet Gynecol. 2015 ; 212 : 114. e1-4.
24) Castanon A, Landy R, Brocklehurst P, et al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England : nested case-control study. BMJ. 2014 ; 349 : g6223.
25) Nam KH, Kwon JY, Kim Y-H, et al. Pregnancy outcome after cervical conization : risk factors for preterm delivery and the efficacy of prophylactic cerclage. J Gynecol Oncol. 2010 ; 21 : 225-9.
26) Miyakoshi K, Itakura A, Abe T, et al. Risk of preterm birth after the excisional surgery for cervical lesions : a propensity-score matching study in Japan. J Matern Fetal Neonatal Med. 2021 ; 34 : 845-51.
P.90 掲載の参考文献
1) Green LJ, Mackillop LH, Salvi D, et al. Gestation-specific vital sign reference ranges in pregnancy. Obstet Gynecol. 2020 ; 135 : 653.
2) Metoki H, Ohkubo T, Watanabe Y, et al : BOSHI Study Group. Seasonal trends of blood pressure during pregnancy in Japan : the babies and their parents'longitudinal observation in Suzuki Memorial Hospital in Intrauterine Period study. J Hypertens. 2008 ; 26 : 2406-13.
3) Ishikuro M, Obara T, Metoki H, et al. Parity as a factor affecting the white-coat effect in pregnant women : The BOSHI study. Hypertens Res. 2015 ; 38 : 770-5.
4) Ishikuro M, Obara T, Metoki H, et al. Blood pressure measured in the clinic and at home during pregnancy among nulliparous and multiparous women : The BOSHI study. Am J Hypertens. 2013 ; 26 : 141-8.
5) Higby K, Suiter CR, Langer O, et al. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol. 1994 ; 171 : 984.
6) Bartal MF, Lindheimer MD, Sibai BM. Proteinuria during pregnancy : definition, pathophysiology, methodology, and clinical significance. Am J Obstet Gynecol. 2022 ; 226 (2S) : S819-S834.
7) Baba Y, Yamada T, Minakami H, et al. Urinary protein-to-creatinine ratio in pregnant women after dipstick testing : prospective observational study. BMC Pregnancy Childbirth. 2015 ; 15 : 331.
8) Phelan LK, Brown MA, Mangos G, et al. A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia. Hypertens Pregnancy. 2004 ; 23 : 135-42.
9) Kreepala C, Srila-on A, Kitporntheranunt M. The association between GFR evaluated by serum cystatin C and proteinuria during pregnancy. Kidney Int Rep. 2019 ; 4 : 854-63.
10) Holston AM, Qian C, Yu KF, et al. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol. 2009 ; 200 : 392.e1-10.
11) Masuyama H, Suwaki N, Nakatsukasa H, et al. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006 ; 194 : 551-6.
12) Macdonald-Wallis C, Nelson SM, Tilling K, et al. Relationships of risk factors for pre-eclampsia with patterns of occurrence of isolated gestational proteinuria during normal term pregnancy. PLoS One. 2011 ; 6 : e22115.
13) Morikawa M, Yamada T, Minakami H. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. J Perinat Med. 2008 ; 36 : 419-24.
14) Shinar S, Asher-Landsberg J, Schwartz A, et al. Isolated proteinuria is a risk factor for pre-eclampsia : a retrospective analysis of the maternal and neonatal outcomes in women presenting with isolatedg estational proteinuria. J Perinatol. 2016 ; 36 : 25-9.
15) Sarno L, Maruotti GM, Saccone G, et al. Pregnancy outcome in proteinuria-onset and hypertension-onset preeclampsia. Hypertens Pregnancy. 2015 ; 34 : 284-90.
16) Yamada T, Obata-Yasuoka M, Hamada H, et al. Isolated gestational proteinuria preceding the diagnosis of preeclampsia-an observational study. Acta Obstet Gynecol Scand. 2016 ; 95 : 1048-54.
17) Saade GR. Proteinuria in pregnancy : much ado about nothing. Am J Obstet Gynecol. 2021 ; 224 : 421.
P.98 掲載の参考文献
1) Foxman B. Urinary tract infection syndromes : occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014 ; 28 : 1-13.
2) Schnarr J, Smaill F. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest. 2008 ; 38 Suppl 2 : 50-7.
3) Whalley P. Bacteriuria of pregnancy. Am J Obstet Gynecol. 1967 ; 97 : 723-38.
4) Kazemier BM, Koningstein FN, Schneeberger C, et al. Maternal and neonatal consequences of treated and untreated asymptomatic bacteriuria in pregnancy : a prospective cohort study with an embedded randomised controlled trial. Lancet Infect Dis. 2015 ; 15 : 1324-33.
5) Macejko AM, Schaeffer AJ. Asymptomatic bacteriuria and symptomatic urinary tract infections during pregnancy. Urol Clin North Am. 2007 ; 34 : 35-42.
6) Hill JB, Sheffield JS, McIntire DD, et al. Acute pyelonephritis in pregnancy. Obstet Gynecol. 2005 ; 105 : 18-23.
7) Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy : an 18-year retrospective analysis. Am J Obstet Gynecol. 2014 ; 210 : 219.e1-6.
8) 日本産科婦人科学会, 日本産婦人科医会, 編, 監修. CQ302 切迫早産の診断と管理の注意点は? 産婦人科診療ガイドライン 産科編 2020. 2020. p.136-41.
9) Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2015 ; CD000490.
10) Sentilhes L, Senat MV, Ancel PY, et al. Prevention of spontaneous preterm birth : Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2017 ; 210 : 217-24.
11) 日本産科婦人科学会, 日本産婦人科医会, 編, 監修. CQ111 尿路感染の診断と治療は?. 産婦人科診療ガイドライン婦人科 外来編 2020. 2020. p.25-7.
12) US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for Asymptomatic Bacteriuria in Adults : US Preventive Services Task Force Recommendation Statement. JAMA. 2019 ; 322 : 1188-94.
13) U. S. Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults : U. S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2008 ; 149 : 43-7.
14) Henderson JT, Webber EM, Bean SI. Screening for Asymptomatic Bacteriuria in Adults : Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 ; 322 : 1195-205.
15) Henderson JT, Webber EM, Bean SI. Screening for Asymptomatic Bacteriuria in Adults : An Updated Systematic Review for the U. S. Preventive Services Task Force. Rockville (MD) : Agency for Healthcare Research and Quality (US) ; 2019.
16) Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005 ; 40 : 643-54.
17) Verani JR, McGee L, Schrag SJ : Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010 ; 59 (RR-10) : 1-36.
18) Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria : 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019 ; 68 : e83-110.
19) Widmer M, Lopez I, Gulmezoglu AM, et al. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev. 2015 ; CD000491.
20) Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018 ; 219 : 40-51.
21) Rogozinska E, Formina S, Zamora J, et al. Accuracy of onsite tests to detect asymptomatic bacteriuria in pregnancy : a systematic review and meta-analysis. Obstet Gynecol. 2016 ; 128 : 495-503.
23) Guinto VT, De Guia B, Festin MR, et al. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2010 ; CD007855.
P.106 掲載の参考文献
1) Engle WA, Tomashek KM, Wallman C. Committee on Fetus and Newborn, American Academy of Pediatrics. "Late-preterm" infants : A population at risk. Pediatrics. 2007 ; 120 : 1390-401.
2) Petrini JR, Dias T, McCormick MC, et al. Increased risk of adverse neurological development for late preterm infants. J Pediatr. 2009 ; 154 : 169-76.
3) Esplin MS, O'Brien E, Fraser A, et al. Estimating recurrence of spontaneous preterm delivery. Obstet Gynecol. 2008 ; 112 : 516-23.
4) Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017 ; 377 : 613-22.
5) Bartsch E, Medcalf KE, Park AL, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy : systemic review and meta-analysis of large cohort studies. BMJ. 2016 ; 353 : 1-10.
6) Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003 ; 348 : 2379-85.
7) 西村玄, 澤井英明, 室月淳, 編. 骨系統疾患-出生前診断と周産期管理. 東京 : メジカルビュー社. 2011.
8) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2020. 2020.
P.112 掲載の参考文献
2) 日本産科婦人科学会, 編. 産婦人科用語集・用語解説集 改訂第4版. 2018.
3) Renzo GCD, Giardina I, Rosati A, et al. Maternal risk factors for preterm birth : a country-based population analysis. Eur J Obstet Gynecol Reproid Biol. 2011 ; 159 : 342-6.
4) Glantz C, Purnell L. Clinical utility of sonography in the diagnosis and treatment of placental abruption. J UItrasound Med. 2002 ; 21 : 837-40.
P.123 掲載の参考文献
1) La Cour Freiesleben N, Egerup P, Hviid KVR, et al. SARS-CoV-2 in first trimester pregnancy : a cohort study. Hum Reprod. 2021 ; 36 : 40-7.
2) Cosma S, Carosso AR, Cusato J, et al. Coronavirus disease 2019 and first-trimester spontaneous abortion : a case-control study of 225 pregnant patients. Am J Obstet Gynecol. 2021 ; 224 : 391.e1-7.
3) Li M, Chen L, Zhang J, et al. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. PLoS One. 2020 ; 15 : e0230295.
4) Cui D, Liu Y, Jiang X, et al. Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta. Ultrasound Obstet Gynecol. 2021 ; 57 : 248-56.
5) Weatherbee BAT, Glover DM, Zernicka-Goetz M. Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester. Open Biol. 2020 ; 10 : 200162.
6) Centers for Disease Control and Prevention (CDC) : Data on COVID-19 during Pregnancy : Severity of Maternal Illness. 2020.
7) Mullins E, Hudak ML, Banerjee J, et al. Pregnancy and neonatal outcomes of COVID-19 : coreporting of common outcomes from PAN-COVID and AAP-SONPM registries. Ultrasound Obstet Gynecol. 2021 ; 57 : 573-81.
8) 日本産婦人科医会. 調査結果COVID-19についての実態調査. 2022年1月12日.
9) 日本産科婦人科学会. 日本におけるCOVID-19妊婦の現状~妊婦レジストリの解析結果. 2022年3月1日.
10) Crovetto F, Crispi F, Liurba E, et al. Impact of SARS-CoV-2 infection on pregnancy outcomes : a population-based study. Clin Infect Dis. 2021 ; 1-25.
11) 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 診療の手引き. 2022年4月15日.
12) Zambrano LD, Ellington S, Strid P, et al. Update : Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status- United States, 2020. MMWR Morb Mortal Wkly. 2020 ; 69 : 1641-7
13) Assiamira F, Monique M. Hedderson, et al. Perinatal complications in individuals in california with or without SARS-CoV-2 infection during pregnancy. JAMA Intern Med. 2022 ; 182 : 503-12.
14) Sugiyama M, Kinoshita N, Ide S, et al. Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19. Gene ; 2021 : 766 : 145.
15) 射場敏明, 比企誠. COVID-19における凝固異常と血栓症. 日血栓止血会誌. 2020 ; 31 : 600-3.
16) Kadir RA, Kobayashi T, Iba T, et al. COVID-19 coagulopathy in pregnancy : Critical review, preliminary recommendations, and ISTH registry-Communication from the ISTH SSC for Women's Health. J Thromb Haemost. 2020 ; 18 : 3086-98.
17) 日本感染症学会. COVID-19に対する薬物治療の考え方 第13.1版. 2022年2月18日.
18) National Institue of Health (NIH). Covid-19 Treatment Guideline.
19) Royal College of Obstetricians and Gynecologists (RCOG). Coronavirus (COVID-19), pregnancy and women's health.
P.131 掲載の参考文献
1) Osser OV, Jokubkiene L, Valentin L. Cesarean section scar defects : Agreement between transvaginal sonographic findings with and without saline contrast enhancement. Ultrasound Obstet Gynecol. 2010 ; 35 : 75-83.
2) van Horenbeeck A, Temmerman M, Dhont M. Cesarean scar dehiscence and irregular uterine bleeding. Obstet Gynecol. 2003 ; 102 : 1137-9.
4) Jeremy B, Bonneau C, Guillo E, et al. Uterine ishtmique transmural hernia : results of its repair on symptoms and fertility. Gynecol Obstet Fertil. 2013 ; 41 : 588-96.
5) Luo L, Niu G, Wang Q, et al. Vaginal repair of cesarean section scar diverticula. J Minim Invasive Gynecol. 2012 ; 19 : 454-8.
6) Fabres C, Aviles G, de la Jara C, et al. The cesarean delivery scar pouch : clinical implications and diagnostic correlation between transvaginal sonography and hysteroscopy. J Ultrasound Med. 2003 ; 22 : 695-700.
7) Monteagudo A, Carreno C, Timor-Tritsch IE. Saline infusion sonohysterog-raphy in nonpregnant women with previous cesarean delivery : the "niche" in the scar. J Ultrasound Med. 2001 ; 20 : 1105-15.
8) Jacobson MT, Osias J, Velasco A, et al. Laparoscopic repair of a uteroperitoneal fistula. JSLS. 2003 ; 7 : 367-9.
9) Donnez O. Cesarean scar defects : Management of an iatrogenic pathology whose prevalence has dramatically increased. Fertil Steril. 2020 ; 113 : 704-16.
10) Osser OV, Jokubkiene L, Valentin L. High prevalence of defects in cesarean section scars at transvaginal ultrasound examination. Ultrasound Obstet Gynecol. 2009 ; 34 : 90-7.
11) Antila-Langsjo RM, JU Maenpaa, Huhtala HS, et al. Cesarean scar defect : a prospective study on risk factors. Am J Obstet Gynecol. 2018 ; 219 : 458.e1-8.
12) Vikhareva Osser O, Valentin L. Risk factors for incomplete healing of the uterine incision after caesarean section. BJOG. 2010 ; 117 : 1119-26.
13) Tahara M, Shimizu T, Shimoura H. Preliminary report of treatment with oral contraceptive pills for intermenstrual vaginal bleeding secondary to a cesarean section scar. Fertil Steril. 2006 ; 86 : 477-9.
14) Fernandez E, Fernandez C, Fabres C, et al. Hysteroscopic correction of cesarean section scars in women with abnormal uterine bleeding. J Am Assoc Gynecol Laparosc. 1996 ; 3 (4, Supplement) : S13.
15) Jacobson MT, Osias J, Velasco A, et al. Laparoscopic repair of a uteroperitoneal fistula. JSLS. 2003 ; 7 : 367-9.
16) Cragin EB. Conservatism in obstetrics. NY Med J. 1916 ; 104 : 1-3.
17) Goetzinger KR, Macones GA. Operative vaginal delivery : current trends in obstetrics. Womens Health (Lond). 2008 ; 4 : 281-90.
18) Betran AP, Ye J, Moller AB, et al. The increasing trend in caesarean section rates : Global, regional and national estimates : 1990-2014. PLoS One. 2016 ; 11 : e0148343.
19) Feng XL, Xu L, Guo Y, et al. Socioeconomic inequalities in hospital births in China between 1988 and 2008. Bull World Health Organ. 2011 ; 89 : 432-41.
20) Lavin JP, Stephens RJ, Miodovnik M, et al. Vaginal delivery in patients with a prior cesarean section. Obstet Gynecol. 1982 ; 59 : 135-48.
21) Menacker F, Declercq E, Macdorman MF. Cesarean delivery : Background, trends, and epidemiology. Semin Perinatol. 2006 ; 30 : 235-41.
22) Martin JA, Hamilton BE, Sutton PD, et al. Births : final data for 2006. Natl Vital Stat Rep. 2009 ; 57 : 1-104.
23) National institutes of Health consensus development conference statement : Vaginal birth after cesarean : new insights March 8-10, 2010. Obstet Gynecol. 2010 ; 115 : 1279-95.
24) World Health Organization. Human Reproduction Programme. WHO statement on caesarean section rates. WHO/RHR/15.02, April 2015. <https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/cs-statement/en/>
25) ACOG Practice Bulletin No. 205 : Vaginal Birth After Cesarean Delivery. Obstet Gynecol. 2019 ; 133 : e110-27.
26) Tanos V, Toney ZA. Uterine scar rupture-prediction, prevention, diagnosis, and management. Best Pract Res Clin Obstet Gynaecol. 2019 ; 59 : 115-31.
27) RCOG Green-Top Guideline No. 45 : Birth after previous caesarean birth. 2015.
28) Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. Guidelines for vaginal birth after previous caesarean birth. Number 155 (Replaces guideline Number 147), February 2005. Int J Gynaecol Obstet. 2005 ; 89 : 319-31.
29) Vikhareva Osser O, Valentin L. Clinical importance of appearance of cesarean hysterotomy scar at transvaginal ultrasonography in nonpregnant women. Obstet Gynecol. 2011 ; 117 : 525-32.
30) Baron J, Weintraub AY, Eshkoli T, et al. The consequences of previous uterine scar dehiscence and cesarean delivery on subsequent births. Int J Gynaecol Obstet. 2014 ; 126 : 120-2.
31) Bujold E, Jastrow N, Simoneau J, et al. Prediction of complete uterine rupture by sonographic evaluation of the lower uterine segment. Am J Obstet Gynecol. 2009 ; 201 : 320.e1-6.
32) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン-産科編 2020. 2020 ; p.199-201.
P.144 掲載の参考文献
1) Lencki SG, Maciulla MB, Eglinton GS. Maternal and umbilical cord serum interleukin levels in preterm labor with clinical chorioamnionitis. Am J Obstet Gynecol. 1994 ; 170 : 1345-51.
2) Palmer WL, Bottle A, Aylin P. Association between day of delivery and obstetric outcomes : observational study. BMJ. 2015 ; 351 : h5774.

第2章 産科救急についての疑問

P.154 掲載の参考文献
1) 下平和久. 超緊急 (グレードA) 帝王切開術. 臨婦産. 2013 ; 67 : 260-5.
2) RCOG. Classification of Urgency of Caesarean Section―A Continuum of Risk (Good Practice No. 11). 2010.
3) Lipman SS, Carvalho B, Cohen SE, et al. Response times for emergency cesarean delivery : use of simulation drills to assess and improve obstetric team performance. J Perinatol. 2013 ; 33 : 259-63.
4) 西本絹代, 野尻恵美子, 野地恵美, 他. 超緊急帝王切開術における取り組みについて. 日赤和歌山医療センター医誌. 2020 ; 37 : 45-50.
5) 上野たまき, 上野有生, 金田大介, 他. 地方都市基幹病院における超緊急帝王切開の取り組みとその効果. 日周産期・新生児会誌. 2014 ; 50 : 982-9.
6) Iitani Y, Tsuda H, Ito Y, et al. Simulation training is useful for shortening the decision-to-delivery interval in cases of emergent cesarean section. J Matern Fetal Neonatal Med. 2018 ; 31 : 1-5.
P.163 掲載の参考文献
1) 高松和弘, 福嶋朋子, 下江豊, 他. 急性期脳卒中の実態 : 脳卒中の病型別にみた初発神経症状の頻度. In : 脳卒中データバンク 2015. 東京 : 中山書店. 2015 ; p.26-7.
2) Knight M. Eclamlpsia in the United Kingdom 2005. Br J Obstet Gynaecol. 2007 ; 114 : 1072-8.
3) 大野泰正. 妊産婦の脳出血への対応を脳神経外科と協働する. 日産婦誌. 2018 ; 70 : 1165-9.
4) Abalos E, Cuesta C, Carroli G, et al. Pre-eclampsia, eclampsia, and adversed maternal and perinatal outcomes : a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014 ; 121 : 14-24.
5) Kuklina EV, Tong X, Bansil P, et al. Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007 : reasons for concern? Stroke. 2011 ; 42 : 2564-70.
6) Yoshida K, Takahashi JC, Takenobu Y, et al. Strokes associated with pregnancy and puerperium : a nationwide study by the Japan Stroke Society. Stroke. 2017 ; 48 : 276-82.
7) 日本妊娠高血圧学会, 編. 妊娠高血圧症候群診療指針 2015. 東京 : メジカルビュー社. 2015 ; p.139-42.
8) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2017. 2017 ; p.199-204.
9) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2020. 2020 ; p.177-80.
10) Duley L, Henderson-Smart D, Walker GJ, et al. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2010 ; 12 : CD000127.
11) Duley L, Henderson-Smart D, Chou D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. 2010 ; 10 : CD000128.
12) WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva : World Health Organization ; 2011.
13) Cipolla MJ, Kraig R. Seizures in women with preeclampsia : mechanisms and management. Fetal Matern Med Rev. 2011 ; 22 : 91-108.
14) 日本神経学会, 監. てんかん診断ガイドライン (2018年改訂版). 東京 : 医学書院. 2018.
15) Staessen JA, Wang JG, Thijs L, et al. Cardiovascular protection and blood pressure reduction : a meta-analysis. Lancet. 2001 ; 358 : 1305-15.
16) Paul RH, Koh KS, Bernstein SG, et al. Changes in fetal heart rate-uterine contraction patterns associated with eclampsia. Am J Obstet Gynecol. 1978 ; 130 : 165-9.
17) Ohno Y, Kawai M, Morikawa S, et al. Management of eclampsia and stroke during pregnancy. Neurol Med Chir. 2013 ; 53 : 513-9.
18) Say L, Chou D, Gemmill A, et al. Global causes of maternal death : a WHO systematic analysis. Lancet Blob Health. 2014 ; 2 : e323-33.
19) Hasegawa J, Sekizawa A, Tanaka H, et al. Current status of pregnancy-related maternal mortality in Japan : a report from the Maternal Death Exploratory Committee in Japan. BMJ Open. 2016 ; 6 : e010304.
20) Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA. 1981 ; 245 : 1225-9.
21) Ohno Y, Terauchi M, Tamakoshi K, et al. Risk factors of labor onset hypertension. Hypertens Res. 2016 ; 39 : 260-5.
22) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2020. 2020 ; p.257-9.
P.172 掲載の参考文献
1) Ohno Y, Terauchi M, Tamakoshi K, et al. The risk factors for labor onset hypertension. Hypertens Res. 2016 ; 39 : 260-5.
3) Committee Opinion No. 692 : Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol. 2017 ; 129 : e90-5.
4) Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy : summary of updated NICE guidance. BMJ. 2019 ; 366 : l5119.
5) Khedun SM, Moodley J, Naicker T, et al. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther. 1997 ; 74 : 221-58.
6) Magee LA, von Dadelszen P, Singer J, et al. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study) : is severe hypertension just an elevated blood pressure? Hypertension. 2016 ; 68 : 1153-9.
7) Cursino T, Katz L, Coutinho I, et al. Diuretics vs. placebo for postpartum blood pressure control in preeclampsia (DIUPRE) : a randomized clinical trial. Reprod Health. 2015 ; 12 : 66.
8) 日本妊娠高血圧学会, 編. 妊娠高血圧症候群の診療指針 2021. 東京 : メジカルビュー社. 2021.
9) Easterling T, Mundle S, Bracken H, et al. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy : an open-label, randomised controlled trial. Lancet. 2019 ; 394 : 1011-21.
10) Duley L, Henderson-Smart D, Walker G, et al. Magnesium sulphate versus diazepam for eclampsia. New Jersey : John Wiley & Sons, Ltd, 2010. p.12.
11) ACOG Practice Bulletin No. 202 : Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019 ; 133 : 1.
12) Duley L, Henderson-Smart DJ, Walker GJA, et al. Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2010 ; 2010 : CD000127.
13) Pratt JJ, Niedle PS, Vogel JP, et al. Alternative regimens of magnesium sulfate for treatment of preeclampsia and eclampsia : a systematic review of non-randomized studies. Acta Obstet Gynecol Scand. 2016 ; 95 : 144-56.
14) Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995 ; 345 : 1455-63.
15) Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial : a randomised placebo-controlled trial. Lancet. 2002 ; 359 : 1877-90.
16) 糸川嘉則, 齊藤昂, 編著. マグネシウム-成人病との関連. 東京 : 光生館. 1995.
P.183 掲載の参考文献
1) 厚生労働省健康局長. 感染症の予防及び感染症の患者に対する医療に関する法律などの改正について. <https://www.mhlw.go.jp/content/000733827.pdf>
2) 倉澤健太郎. 新型コロナウイルス感染妊婦の受け入れ体制の構築. In : 橋井康二, 他編. 産科の感染防御ガイド. 大阪 : メディカ出版. 2020 ; p.62-72.
3) 厚生労働省. 災害医療コーディネーター活動要領及び災害時小児周産期リエゾン活動要領について. <https://www.mhlw.go.jp/content/10800000/000478142.pdf>
4) 神奈川県. 妊婦, 新生児のいのちを守る「周産期コロナ受入医療機関」の設置について. <http://www.pref.kanagawa.jp/docs/ga4/covid19/ms/hybrid_20200525.html>
P.193 掲載の参考文献
1) Sato M, Kondoh E, Iwao T, et al. Nationwide survey of severe postpartum hemorrhage in Japan : an exploratory study using the national database of health insurance claims. J Matern Fetal Neonatal Med. 2019 ; 32 : 3537-42.
2) 近藤英治. 経腟分娩時の大量出血に対する対処法. In : 平松祐司, 編. 産科手術を極める. OGS NOW basic 5. 東京 : メジカルビュー社 ; 2021.
3) Kondoh E, Chigusa Y, Ueda A, et al. CT scan assessment of intrauterine balloon tamponade failure for the treatment of atonic postpartum hemorrhage : implications for treatment. BJOG. 2021 ; 128 : 1726-31.
4) Kondoh E, Chigusa Y, Ueda A, et al. Novel intrauterine balloon tamponade systems for postpartum hemorrhage. Acta Obstet Gynecol Scand. 2019 ; 98 : 1612-7.
5) Ikeda A, Kondoh E, Chigusa Y, et al. Novel subtype of atonic postpartum hemorrhage : dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. J Matern Fetal Neonatal Med. 2020 ; 33 : 3286-92.
6) Kondoh E, Chigusa Y, Ueda A, et al. Ultrasound findings of a novel subtype of atonic postpartum hemorrhage : still a diagnosis of exclusion? Hypertens Res Pregnancy. 2019 ; 7 : 39-40.
7) Kondoh E, Ueda A. Reply : The Kyoto balloon system for postpartum hemorrhage : a hard balloon shaft offers an easier and surer way to apply direct pressure on bleeding sites. Acta Obstet Gynecol Scand. 2020 ; 99 : 292-3.
P.201 掲載の参考文献
1) Soyer P, Dohan A, Dautry R, et al. Transcatheter arterial embolization for postpartum hemorrhage : indications, technique, results, and complications. Cardiovas and intervent radio. 2015 ; 38 : 1068-81.
2) Sierra A, Burrel M, Sebastia C, et al. Utility of multidetector CT in severe postpartum hemorrhage. Radiographics. 2012 ; 32 : 1463-81.
3) Lee NK, Kim S, Kim CW, et al. Identification of bleeding sites in patients with postpartum hemorrhage : MDCT compared with angiography. AJR Am J Roentgenol. 2010 ; 194 : 383-90.
4) Jung YM, Kim HJ, Choi WS, et al. CT angiography for the management of postpartum hemorrhage refractory to conservative treatment. J Matern Fetal Neonatal Med. 2020 ; 1-8.
5) Tanahashi Y, Goshima S, Kondo H, et al. Transcatheter arterial embolization for primary postpartum hemorrhage : Predictive factors of need for embolic material conversion of gelatin sponge particles to N-butyl cyanoacrylate. Cardiovas Intervent Radio. 2017 ; 40 : 236-44.
6) Kim JE, So YH, Kim BJ, et al. Postpartum hemorrhage from non-uterine arteries : Clinical importance of their detection and the results of selective embolization. Acta Radiol. 2018 ; 59 : 932-8.
7) Katsumori T, Kasahara T. The size of gelatin sponge particles : differences with preparation method. Cardiovas Intervent radio. 2006 ; 29 : 1077-83.
8) 森墾, 齋田幸久, 渡邊祐子, 他. ゼラチンスポンジ細片の簡易作成法-ポンピング法-. 日本医放会誌. 2000 ; 60 : 702-4.
P.214 掲載の参考文献
1) Kanayama N, Tamura N. Amniotic fluid embolism : Pathophysiology and new strategies for management. J Obstet Gynaecol Res. 2014 ; 40 : 1507-17.
2) 妊産婦死亡症例検討評価委員会, 日本産婦人科医会. 母体安全への提言 2019. 2020. p.11-5.
3) Oda T, Tamura N, Ide R, et al. Consumptive coagulopathy involving amniotic fluid embolism : the importance of earlier assessments for interventions in critical care. Crit Care Med. 2020 ; 48 : e1251-9.
4) 妊産婦・胎児死亡減少のための小委員会. 羊水塞栓症の子宮所見の臨床的検討 (周産期委員会報告). 日産婦誌. 2017 ; 69 : 1467-9.
5) 光畑裕正. 2. アナフィラキシーとの臨床診断, アナフィラキシーショック. 東京 : 克誠堂出版. 2008 ; p.61-80.
6) 日本産科婦人科学会, 日本産婦人科医会, 日本周産期・新生児医学会, 他. 産科危機的出血への対応指針 2017. 2017.
7) 溝端康光. Damage control surgery : 理論的背景と実際. 救急集中治療. 2014 ; 26 : 995-1003.
8) Todo Y, Tamura N, Itoh H, et al. Therapeutic application of C1 esterase inhibitor concentrate for clinical amniotic fluid embolism : a case report. Clin Case Rep. 2015 ; 3 : 673-5.
P.220 掲載の参考文献
1) 妊産婦死亡症例検討評価委員会, 日本産婦人科医会. 母体安全への提言 2019. 2020.
2) 宮田茂樹, 板倉敦夫, 上田裕一, 他. 大量出血症例に対する血液製剤の適正な使用のガイドライン. Japanese Journal of Transfusion and Cell Therapy. 2019 ; 65 : 21-92.
3) Makino S, Takeda S, Kondoh E, et al. National survey of uterine rupture in Japan : Annual report of Perinatology Committee, Japan Society of Obstetrics and Gynecology, 2018. J Obstet Gynaecol Res. 2019 ; 45 : 763-5.
4) Wikkelso AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage : randomized controlled trial. Br J Anaesth. 2015 ; 114 : 623-33.
5) Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage : OBS2, a double-blind randomized controlled trial. Br J Anaesth. 2017 ; 119 : 411-21.
8) Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage-an observational study. Transfus Med. 2012 ; 22 : 344-9.
9) Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage : a multicenter, randomized, open controlled trial. J Thromb Haemost. 2015 ; 13 : 520-9.
10) Patient Blood Management Guidelines. Module 5 Obstetrics and Maternity. 2015.
11) Prevention and Management of Postpartum Haemorrhage. Green-top Guideline No. 52. BJOG. 2017 ; 124 : e106-49.
12) Committee on Practice Bulletins Obstetrics. Practice Bulletin No. 183 : postpartum hemorrhage. Obstet Gynecol. 2017 ; 130 : e168-86.
P.227 掲載の参考文献
1) 日本産婦人科医会 妊産婦死亡症例検討評価委員会, 編. 母体安全への提言 2019 (Vol. 10). 2020. <http://www.jaog.or.jp/wp/wp-content/uploads/2020/111/botai_2019.pdf>
2) 日本産婦人科医会 妊産婦死亡症例検討評価委員会, 編. 母体安全への提言 2014 (Vol. 5). 2015. <http://www.jaog.or.jp/wp/wp-content/uploads/2017/01/botai_2014.pdf>
3) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2020. 2020.
4) 日本産婦人科医会 妊産婦死亡症例検討評価委員会, 編. 母体安全への提言 2015 (Vol. 6). 2016. <http://www.jaog.or.jp/wp/wp-content/uploads/2017/01/botai_2015.pdf>
5) Lee HJ, Cho HY, Peck MJ, et al. Uterine artery embolization versus cesarean hysterectomy in the management of postpartum hemorrhage. Minim Invasive Ther Allied Technol. 2019 ; 28 : 351-8.
6) 日本産婦人科医会 妊産婦死亡症例検討評価委員会, 編. 母体安全への提言 2016 (Vol. 7). 2017 (2018 改定). <http://www.jaog.or.jp/wp/wp-content/uploads/2017/08/botai_2016_2.pdf>
7) 厚生労働省Webサイト. 夜間休日精神科救急医療機関案内窓口. <https://www.mhlw.go.jp/kokoro/support/ercenter.html>
長谷川潤一. 妊産婦死亡報告事業 2019 2010年~2019年に集積した事例の解析結果. 2020. <https://www.jaog.or.jp/wp/wp-content/uploads/2020/11/e147d306dd675338de60013905478f3f.pdf>
P.236 掲載の参考文献
1) Katz V, Dotters DJ, Droegemueller W. Perimortem caesarean delivery. Obstet Gynecol. 1986 ; 68 : 571-6.
2) Goto M, Watanabe H, Ogita K, et al. Perimortem cesarean delivery and subsequent emergency hysterectomy : new strategy for maternal cardiac arrest. Acute Med Surg. 2017 ; 4 : 467-71.
3) Benson MD, Padovano A, Bourjeily G, et al. Maternal collapse : challenging the four-minute rule. EBio Med. 2016 ; 6 : 253-7.
4) Perinatal Critical Care Course運営協議会. 周産期初期診療アルゴリズム : PC3ピーシーキューブ公式コースガイド. 大阪 : メディカ出版. 2017.
P.243 掲載の参考文献
1) 妊産婦死亡症例検討評価委員会, 日本産婦人科医会. 母体安全への提言 2019. 2020.
2) Hasegawa J, Wakasa T, Matsumoto H, et al. Analysis of maternal death autopsies from the nationwide registration system of maternal deaths in Japan. J Matern Fetal Neonatal Med. 2018 ; 31 : 333-8.
3) 妊産婦死亡時の剖検と病理検査の指針作成委員会. 妊産婦死亡剖検マニュアル 改訂版. 2016.
P.255 掲載の参考文献
1) 日本産婦人科医会. 医療安全部会. 分娩に関する調査 2017.
2) 日本麻酔科学会. 安全な麻酔のためのモニター指針 (第3版). 2014年7月. <http://www.anesth.or.jp/guide/pdf/monitor3.pdf>
3) 日本麻酔科学会. 局所麻酔薬中毒への対応プラクティカルガイド. 2017年6月. <http://www.anesth.or.jp/files/pdf/practical_localanesthesia.pdf>
5) Datta S, Lambert DH, Gregus J, et al. Differential sensitivities of mamalian nerve fibers during pregnancy. Anesthesiology. 1983 ; 62 : 1070-2.
6) Oda Y. Lipid resuscitation : development in basic research and application to clinical practice. J Anesth. 2013 ; 27 : 811-4.
7) 無痛分娩の安全な提供体制の構築に関する提言. 2018年3月. <https://www.jalasite.org/doc/wp-content/uploads/2018/12/10.-研究班提言.pdf>
8) Kariya N, Kawasaki Y, Okutani H, et al. Effects of simulation study of high neuraxial block during epidural analgesia for labor pain on pre/posttest evaluation in junior clinical trainees : Anesth Pain Med. 2020 ; 10 : e100045.
9) Austin N, Goldhaber-Fiebert S, Daniels K, et al. Building comprehensive strategies for obsteric safety : simulation drills and communication. Anesth Analg. 2016 ; 123 : 1181-90.
P.262 掲載の参考文献
1) Bauer ME, Bateman BT, Bauer ST, et al. Maternal sepsis mortality and morbidity during hospitalization for delivery : Temporal trends and independent associations for severe sepsis. Anesth Analg. 2013 ; 117 : 944-50.
2) Al-Ostad G, Kezouh A, Spence AR, et al. Incidence and risk factors of sepsis mortality in labor, delivery and after birth : population-based study in the USA. J Obstet Gynaecol Res. 2015 ; 41 : 1201-6.
3) Barton JR, Sibai BM. Severe sepsis and septic shock in pregnancy. Obstet Gynecol. 2012 ; 120 : 689.
4) 妊産婦死亡症例検討評価委員会, 日本産婦人科医会. 母体安全への提言 2019. 2020. p.9-15.
5) 早田英二郎. その他の感染症-オウム病, 結核, 大腸菌等. In : 関沢明彦, 他, 編. 日本の妊産婦を救うために 2020. 東京 : 東京医学社. 2020 ; p.304-9.
6) Hasegawa J, Sekizawa A, Yoshimatsu J, et al. Cases of death due to serious group A streptococcal toxic shock syndrome in pregnant females in Japan. Arch Gynecol Obstet. 2015 ; 291 : 5-7.
7) Leonard A, Wright A, Saavedra-Campos M, et al. Severe group A streptococcal infections in mothers and their newborns in London and the South East, 2010-2016 : assessment of risk and audit of public health management. BJOG. 2019 ; 126 : 44-53.
9) McIsaac WJ, Kellner JD, Aufricht P, et al. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA. 2004 ; 291 : 1587-95.
10) Hayata E, Nakata M, Hasegawa J, et al. Nationwide study of mortality and survival in pregnancy-related streptococcal toxic shock syndrome. J Obstet Gynaecol Res. 2021 ; 47 : 928-34.
11) Ferrer R, Martin-Loeches I, Dellinger RP, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour : results from a guideline-based performance improvement program. Crit Care Med. 2014 ; 42 : 1749-55.
12) Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign : International Guidelines for Management of Sepsis and Septic Shock : 2016. Intensive Care Med. 2017 ; 43 : 304-77.
P.272 掲載の参考文献
1) Fransen AF, van de Ven J, Merien AE, et al. Effect of obstetric team training on team performance and medical technical skills, a randomised controlled trial. BJOG. 2012 ; 119 : 1387-93.
2) Yucel C, Hawley G, Terzioglu F, et al. The effectiveness of simulation-based team training in obstetrics emergencies for improving technical skills : a systematic review. Simul Healthc. 2020 ; 15 : 98-105.
3) 日本母体救命システム普及協議会. 母体急変時の初期対応 第3版. 大阪 : メディカ出版, 2020 ; p.29-272.

第3章 児の長期予後についての疑問

P.278 掲載の参考文献
1) Holland G, Tiggemann M. A systematic review of the impact of the use of social networking sites on body image and disordered eating outcomes. Body Image. 2016 ; 17 : 100-10.
2) 須田史朗. 摂食障害患者の妊娠・出産, 育児. 精神科治療. 2012 ; 27 : 1351-5.
3) Hoffman ER, Zerwas SC, Bulik CM. Reproductive issues in anorexia nervosa. Expert Rev Obstet Gynecol. 2011 ; 6 : 403-14.
4) 榧野真美, 吉内一浩. 神経性やせ症患者の妊娠出産. 日心療内誌. 2014 ; 18 : 166-9.
5) Enomoto K, Aoki S, Toma R, et al. Pregnancy outcomes based on pre-pregnancy body mass index in Japanese women. PLoS One. 2016 ; 11 : e0157081.
6) Fujiwara K, Aoki S, Kurasawa K, et al. Associations of maternal pre-pregnancy underweight with small-for-gestational-age and spontaneous preterm birth, and optimal gestational weight gain in Japanese women. J Obstet Gynaecol Res. 2014 ; 40 : 988-94.
7) Ikenoue S, Miyakoshi K, Kasuga Y, et al. Impaired fetal growth in mothers with inadequate gestational weight gain : a retrospective study in Japanese uncomplicated pregnancy. J Matern Fetal Neonatal Med. 2020 ; 33 : 2227-31.
8) Morisaki N, Kawachi I, Oken E, et al. Parental characteristics can explain why Japanese women give birth to the smallest infants in the United States. Paediatr Perinat Epidemiol. 2016 ; 30 : 473-8.
9) Murai U, Nomura K, Kido M, et al. Pre-pregnancy body mass index as a predictor of low birth weight infants in Japan. Asia Pac J Clin Nutr. 2017 ; 26 : 434-7.
10) Ogawa K, Matsushima S, Urayama KY, et al. Association between adolescent pregnancy and adverse birth outcomes, a multicenter cross sectional Japanese study. Sci Rep. 2019 ; 9 : 2365.
11) Kasuga Y, Kim SH, Suzuki T, et al. Is the risk of small for gestational age influenced by maternal body composition in young Japanese women? J Matern Fetal Neonatal Med. 2020 ; 33 : 1628-30.
12) Kasuga Y, Shigemi D, Tamagawa M, et al. Size for gestational age at birth according to offspring sex and gestational weight gain in underweight women. J Dev Orig Health Dis. 2019 ; 10 : 536-41.
13) Zanetti D, Tikkanen E, Gustafsson S, et al. Birthweight, type 2 diabetes mellitus, and cardiovascular disease : addressing the Barker hypothesis with Mendelian randomization. Circ Genom Precis Med. 2018 ; 11 : e002054.
15) Boney CM, Verma A, Tucker R, et al. Metabolic syndrome in childhood : association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005 ; 115 : e290-6.
16) Schieve LA, Tian LH, Rankin K, et al. Population impact of preterm birth and low birth weight on developmental disabilities in US children. Ann Epidemiol. 2016 ; 26 : 267-74.
17) Breslau N, Paneth NS, Lucia VC. The lingering academic deficits of low birth weight children. Pediatrics. 2004 ; 114 : 1035-40.
18) Ante Z, Luu TM, Healy-Profitos J, et al. Pregnancy outcomes in women with anorexia nervosa. Int J Eat Disord. 2020 ; 53 : 403-12.
19) Stewart DE, Raskin J, Garfinkel PE, et al. Anorexia nervosa, bulimia, and pregnancy. Am J Obstet Gynecol. 1987 ; 157 : 1194-8.
20) Bulik CM, Von Holle A, Siega-Riz AM, et al. Birth outcomes in women with eating disorders in the Norwegian Mother and Child cohort study (MoBa). Int J Eat Disord. 2009 ; 42 : 9-18.
21) 高橋美惠子. ダメダメ指導にさようなら 栄養指導の○と× 神経性食欲不振症合併妊娠の栄養指導. Nutrition Care. 2012 ; 5 : 1117-24.
P.289 掲載の参考文献
1) 日本肥満学会. 肥満症診療ガイドライン 2016. 東京 : ライフサイエンス出版. 2016 ; p.1-4.
2) 厚生労働省. 国民健康・栄養調査. 2020. <https://www.mhlw.go.jp/bunya/kenkou/kenkou_eiyou_chousa.html>
3) Weiss JL, Malone FD, Emig D, et al. Obesity, obstetric complications and cesarean delivery rate--a population-based screening study. Am J Obstet Gynecol. 2004 ; 190 : 1091-7.
4) Stothard KJ, Tennant PW, Bell R, et al. Maternal overweight and obesity and the risk of congenital anomalies : a systematic review and meta analysis. JAMA. 2009 ; 301 : 636-50.
5) Enomoto K, Aoki S, Toma R, et al. Pregnancy outcomes based on pre-pregnancy body mass index in japanese women. PLoS One. 2016 ; 11 : e0157081.
6) D'Souza R, Horyn I, Pavalagantharajah S, et al. Maternal body mass index and pregnancy outcomes : a systematic review and meta analysis. Am J Obstet Gynecol MFM. 2019 ; 1 : 100041.
7) Morisaki N, Nagata C, Jwa SC, et al. Pre-pregnancy BMI-specific optimal gestational weight gain for women in Japan. J Epidemiol. 2017 ; 10 : 492-8.
8) 日本産科婦人科学会周産期委員会報告. 2021.
9) Barker DJ, Osmond. C. Infant mortality, childhood nutrition, and ischaemic heart disease in England and Wales. Lancet. 1986 ; 8489 : 1077-81.
10) Gluckman P, Hanson MA. Living with the past : evolution, development, and patterns of disease. Science. 2004 ; 305 : 1733-6.
11) Harder T, Rodekamp E, Schellong K, et al. Birth weight and subsequent risk of type 2 diabetes : a meta-analysis. Am J Epidemiol. 2007 ; 165 : 849-57.
12) Boney CM, Verma A, Tucker R, et al. Metabolic syndrome in childhood : association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics. 2005 ; 115 : e290-6.
13) Yu Z, Han S, Zhu J, et al. Pre-pregnancy body mass index in relation to infant birth weight and offspring overweight/obesity : a systematic review and meta-analysis. PLoS One. 2013 ; 8 : e61627.
14) Linner A, Almgren M. Epigenetic programming-the important first 1000 days. Acta Paediatr. 2020 ; 109 : 443-52.
15) Masuyama H, Mitsui T, Nobumoto E, et al. Effects of a high fat diet exposure in utero on the metabolic syndrome-like phenomenon in mouse offspring through epigenetic changes in adipocytokine gene expressions. Endocrinology. 2012 ; 153 : 2823-30.
16) Stephenson J, Heslehurst N, Hall J, et al. Before the beginning : nutrition and lifestyle in the preconception period and its importance for future health. Lancet. 2018 ; 391 : 1830-41.
17) McAuliffe FM, Killeen SL, Jacob CM, et al. Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO pregnancy and non-communicable diseases committee : a FIGO (International Federation of Gynecology and Obstetrics) guideline. Int J Gynaecol Obstet. 2020 ; 151 : 16-36.
18) Mameli C, Mazzantini S, Zuccotti GV. Nutrition in the first 1000 days : the origin of childhood obesity. Int J Environmental Res and Public Health. 2016 ; 13 : 838.
P.296 掲載の参考文献
1) Akagawa S, Akagawa Y, Yamanouchi S, et al. Development of the gut microbiota and dysbiosis in children. Biosci Microbiota Food Health. 2021 ; 40 : 12-8.
2) Tamburini S, Shen N, Wu HC, et al. The microbiome in early life : Implications for health outcomes. Nat Med. 2016 ; 22 : 713-22.
3) Tochitani S. Vertical transmission of gut microbiota : Points of action of environmental factors influencing brain development. Neurosci Res. 2021 ; 168 : 83-94.
4) Derrien M, Alvarez AS, de Vos WM. The gut microbiota in the first decade of life. Trends Microbiol. 2019 ; 27 : 997-1010.
5) Chu DM, Antony KM, Ma J, et al. The early infant gut microbiome varies in association with a maternal high-fat diet. Genome Med. 2016 ; 8 : 77.
6) Ma J, Prince AL, Bader D, et al. High-fat maternal diet during pregnancy persistently alters the offspring microbiome in a primate model. Nat Commun. 2014 ; 5 : 3889.
7) Val-Laillet D, Besson M, Guerin S, et al. A maternal Western diet during gestation and lactation modifies offspring's microbiota activity, blood lipid levels, cognitive responses, and hippocampal neurogenesis in Yucatan pigs. FASEB J. 2017 ; 31 : 2037-49.
8) Kapourchali FR, Cresci GAM. Early-Life gut microbiome-the importance of maternal and infant factors in its establishment. Nutr Clin Pract. 2020 ; 35 : 386-405.
9) Lundgren SN, Madan JC, Emond JA, et al. Maternal diet during pregnancy is related with the infant stool microbiome in a delivery mode-dependent manner. Microbiome. 2018 ; 6 : 109.
10) Zhou P, Zhou Y, Liu B, et al. Perinatal antibiotic exposure affects the transmission between maternal and neonatal microbiota and is associated with early-onset sepsis. mSphere. 2020 ; 5 : e00984-19.
11) Aloisio I, Quagliariello A, De Fanti S, et al. Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions. Appl Microbiol Biotechnol. 2016 ; 100 : 5537-46.
12) Wang S, Egan M, Ryan CA, et al. A good start in life is important-perinatal factors dictate early microbiota development and longer term maturation. FEMS Microbiol Rev. 2020 ; 44 : 763-81.
13) Hermansson H, Kumar H, Collado MC, et al. Breast milk microbiota is shaped by mode of delivery and intrapartum antibiotic exposure. Front Nutr. 2019 ; 6 : 4.
14) Turta O, Rautava S. Antibiotics, obesity and the link to microbes-what are we doing to our children? BMC Med. 2016 ; 14 : 57.
15) Tormo-Badia N, Hakansson A, Vasudevan K, et al. Antibiotic treatment of pregnant non-obese diabetic mice leads to altered gut microbiota and intestinal immunological changes in the offspring. Scand J Immunol. 2014 ; 80 : 250-60.
16) Azad MB, Konya T, Guttman DS, et al. Infant gut microbiota and food sensitization : associations in the first year of life. Clin Exp Allergy. 2015 ; 45 : 632-43.
17) Simonyte Sjodin K, Hammarstrom ML, Ryden P, et al. Temporal and long-term gut microbiota variation in allergic disease : A prospective study from infancy to school age. Allergy. 2019 ; 74 : 176-85.
18) Yassour M, Vatanen T, Siljander H, et al. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci Transl Med. 2016 ; 8 : 343ra81.
P.303 掲載の参考文献
1) Dabelea D, Pettitt DJ. Intrauterine diabetic environment confers risks for type 2 diabetes mellitus and obesity in the offspring, in addition to genetic susceptibility. J Pediatr Endocrinol Metab. 2001 ; 14 : 1085-91.
2) Kawasaki M, Arata N, Miyazaki C, et al. Obesity and abnormal glucose tolerance in offspring of diabetic mothers : a systematic review and meta-analysis. PLoS ONE. 2018 ; 13 : e0190676.
3) Moore TR. Fetal exposure to gestational diabetes contributes to subsequent adult metabolic syndrome. Am J Obstet Gynecol. 2010 ; 202 : 643-9.
4) Sauder KA, Hockett CW, Ringham BM, et al. Fetal overnutrition and offspring insulin resistance and β-cell function : the Exploring Perinatal Outcomes among Children (EPOCH) study. Diabet Med. 2017 ; 34 : 1392-9.
5) Pettitt DJ, Aleck KA, Baird HR, et al. Congenital susceptibility to NIDDM. Role of intrauterine environment. Diabetes. 1988 ; 37 : 622-8.
6) Silverman BL, Metzger BE, Cho NH, et al. Impaired glucose tolerance in adolescent offspring of diabetic mothers. Relationship to fetal hyperinsulinism. Diabetes Care. 1995 ; 18 : 611-7.
7) HAPO Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int J Gynaecol Obstet. 2002 ; 78 : 69-77.
8) Sacks DA, Hadden DR, Maresh M, et al ; HAPO Study Cooperative Research Group. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria : the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care. 2012 ; 35 : 526-8.
9) Lowe WL Jr, Scholtens DM, Lowe LP, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA. 2018 ; 320 : 1005-16.
10) Lowe WL Jr, Lowe LP, Kuang A, et al. Maternal glucose levels during pregnancy and childhood adiposity in the hyperglycemia and adverse pregnancy outcome follow-up study. Diabetologia. 2019 ; 62 : 598-610.
11) Lakshman R, Elks CE, Ong KK. Childhood obesity. Circulation. 2012 ; 126 : 1770-9.
12) Lowe WL Jr, Scholtens DM, Kuang A, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS) : Maternal gestational diabetes mellitus and childhood glucose metabolism. Diabetes Care. 2019 ; 42 : 372-80.
13) Kansra AR, Lakkunarajah S, Jay MS. Childhood and adolescent obesity : a review. Front Pediatr. 2021 ; 8 : 581461.
14) Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes : a systematic review and meta-analysis. Lancet. 2009 ; 373 : 1773-9.
15) Vounzoulaki E, Khunti K, Abner SC, et al. Progression to type 2 diabetes in women with a known history of gestational diabetes : systematic review and meta-analysis. BMJ. 2020 ; 369 : m1361.
16) 和栗雅子. 新基準によって診断された妊娠糖尿病既往女性の糖代謝予後に関する研究~4施設における産後5 年までの連続データの解析結果~. 平成26年度厚生労働科学研究費補助金 (循環器疾患・糖尿病等生活習慣病対策総合研究事業) 分担研究報告書. 2015. p.19-29.
17) 日本産科婦人科学会, 日本産婦人科医会, 編. 産婦人科診療ガイドライン 産科編 2020. 2020 ; p.25-8.
P.312 掲載の参考文献
1) Robert L, McInnes RR, Willard HF. Thompson & Thompson Genetics in Medicine, 8th ed. Philadelphia : Elsevier. 2016. p.285.
2) Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs : a prospective cohort study of the EURAP registry. Lancet Neurol. 2018 ; 17 : 530-8.
3) Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy : a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res. 2008 ; 81 : 1-13.
4) Patorno E, Huybrechts KF, Bateman BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017 ; 376 : 2245-54.
5) Berard A, Iessa N, Chaabane S, et al. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy : a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 ; 81 : 589-604.
6) 厚生労働省. 重篤副作用疾患別対応マニュアル. 新生児薬物離脱症候群.
7) Ornoy A, Koren G. SSRIs and SNRIs (SRI) in Pregnancy : effects on the course of pregnancy and the offspring : How far are we from having all the answers? Int J Mol Sci. 2019 ; 20 : 2370.
8) Cohen MJ, Meador KJ, May R, et al. Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age : The NEAD prospective observational study. Epilepsy Behav. 2019 ; 92 : 154-64.
11) Christensen J, Pedersen L, Sun Y, et al. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Netw Open. 2019 ; 2 : e186606.
12) Cohen MJ, Meador KJ, May R, et al. Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age : The NEAD prospective observational study. Epilepsy Behav. 2019 ; 92 : 154-64.
13) Bech LF, Polcwiartek C, Kragholm K, et al. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry. 2018 ; 89 : 1324-31.
14) Meador KJ, Baker GA, Browning N, et al. Breastfeeding in children of women taking antiepileptic drugs : cognitive outcomes at age 6 years. JAMA Pediatr. 2014 ; 168 : 729-36.
15) Titze K, Koch S, Helge H, et al. Prenatal and family risks of children born to mothers with epilepsy : effects on cognitive development. Dev Med Child Neurol. 2008 ; 50 : 117-22.
16) Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016 ; 170 : 117-24.
17) Brown HK, Hussain-Shamsy N, Lunsky Y, et al. The association between antenatal exposure to selective serotonin reuptake inhibitors and autism : a systematic review and meta-analysis. J Clin Psychiatry. 2017 ; 78 : e48-58.
18) Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2015 ; 20 : 727-34.
19) Morales DR, Slattery J, Evans S, et al. Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder : systematic review of observational studies and methodological considerations. BMC Med. 2018 ; 16 : 6.
21) Gadot Y, Koren G. The use of antidepressants in pregnancy : Focus on maternal risks. J Obstet Gynaecol Can. 2015 ; 37 : 56-63.

最近チェックした商品履歴

Loading...